• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEL AM filed by Black Hawk Acquisition Corporation

    12/29/25 2:51:31 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BKHA alert in real time by email
    DEL AM 1 blackhawk_delam.htm DEL AM

     

    Black Hawk Acquisition Corporation

    125 Blackhawk Plaza Circle, Suite 166

    Danville, CA 94506

     

    December 29, 2025

     

    VIA EDGAR

     

    Securities and Exchange Commission

    Division of Investment Management

    100 F Street, N.E.

    Washington, D.C. 20549

     

    Re: Black Hawk Acquisition Corporation Registration Statement on Form S-4
      (File No. 333-292402)

     

    Ladies and Gentlemen:

     

    Pursuant to Rule 473 under the Securities Act of 1933, as amended (the “Securities Act”), the registrant is hereby filing a delaying amendment with respect to its Registration Statement on Form S-4 (File No. 333-292402) relating to the initial registration of the registrant. The Registration Statement was filed with the Securities and Exchange Commission (the “Commission”) on December 23, 2025.

     

    The Registrant hereby amends the Registration Statement to delay its effective date until the Registrant shall file a further amendment which specifically states that the Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.

     

    Pursuant to the requirements of the Securities Act and Rule 478 thereunder, this delaying amendment has been signed on behalf of the registrant, in the City of New York and the State of New York, on the 29th day of December 2025.

     

    Sincerely,

     

    /s/ Kent Kaufman  
    Kent Kaufman  
    Chief Executive Officer and Chairman  

     

       

     

     

    Get the next $BKHA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BKHA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BKHA
    SEC Filings

    View All

    SEC Form 10-Q filed by Black Hawk Acquisition Corporation

    10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/20/26 6:23:25 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-Q filed by Black Hawk Acquisition Corporation

    NT 10-Q - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/14/26 4:14:17 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Hawk Acquisition Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Black Hawk Acquisition Corp (0002000775) (Filer)

    4/1/26 4:56:37 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Black Hawk Acquisition Corporation

    SC 13G/A - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/15/24 9:17:26 AM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 8:39:26 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Hawk Acquisition Corporation

    SC 13G - Black Hawk Acquisition Corp (0002000775) (Subject)

    11/14/24 6:13:30 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BKHA
    Leadership Updates

    Live Leadership Updates

    View All

    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

    BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer. "Dr. Tolentino

    3/18/26 10:42:50 PM ET
    $BKHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care